Synlogic Share Holder Equity 2013-2024 | SYBX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Synlogic share holder equity from 2013 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Synlogic share holder equity from 2013 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.8B
Regeneron Pharmaceuticals (REGN)	$126.4B
Vertex Pharmaceuticals (VRTX)	$124.2B
Gilead Sciences (GILD)	$103.4B
Bristol Myers Squibb (BMY)	$100.3B
CSL (CSLLY)	$97.4B
GSK (GSK)	$88.2B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Argenex SE (ARGX)	$31.2B
BioNTech SE (BNTX)	$29.7B
Biogen (BIIB)	$28.9B
Moderna (MRNA)	$27.7B
Illumina (ILMN)	$20.7B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.5B
BioMarin Pharmaceutical (BMRN)	$13.4B
Vaxcyte (PCVX)	$13B
Incyte (INCY)	$12.8B
Insmed (INSM)	$12.6B
Exact Sciences (EXAS)	$12.6B
Sarepta Therapeutics (SRPT)	$12B
Bio-Techne Corp (TECH)	$11.9B
QIAGEN (QGEN)	$10.4B
Legend Biotech (LEGN)	$9.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.5B
Intra-Cellular Therapies (ITCI)	$7.9B
Exelixis (EXEL)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B